The MajesTEC-5 trial shows teclistamab's impressive efficacy in achieving MRD-negative status in newly diagnosed transplant-eligible patients, explains Marc S. Raab, MD, PhD.
Marc S. Raab, MD, PhD
Advertisement
Articles by Marc S. Raab, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis
2
Nerandomilast a "No-Brainer" for First-Line Pulmonary Fibrosis Therapy: Justin M. Oldham, MD, PhD, MS
3
New Insight on Biologic Initiation Patterns for Treating Severe Asthma
4
Planetary Health Highlights Global Links Between Climate, Respiratory Well-Being
5
